EULAR 2023  | congress satellite symposia & consult the expert

A number of satellite symposia and consult the expert events will be organised during EULAR 2023, 31 May - 3 June. The full programme will be updated on this page.

Satellite symposia and Consult the Expert are governed by the EULAR Code of Practice, and are strictly prohibited during the official programme hours. All symposia and special events must be approved by EULAR.

SCHEDULE OVERVIEW*

Full programme overview tbd
 

WEDNESDAY 31 May

18:30 - 19:45 Satellite symposia (6 parallel sessions)
15:45 - 16:15 Consult the Expert (3 parallel sessions)

THURSDAY 1 JUNE

08:15 - 09:30 Satellite symposia (6 parallel sessions)
09:45 - 10:15 Consult the Expert (2 parallel sessions)
15:00 - 15:30

Consult the Expert (3 parallel sessions)

17:30 - 18:45 Satellite symposia (8 parallel sessions)

FRIDAY 2 JUNE

08:15 - 09:30 Satellite symposia (7 parallel sessions)
09:45 - 10:15 Consult the Expert (3 parallel sessions)
15:00 - 15:30 Consult the Expert (1 parallel sessions)
17:30 - 18:45 Satellite symposia (2 parallel sessions)

 

Satellite Symposia Programme overview

31 May I 18:30 – 19:45 CEST
AbbVie - Tailor-made Care – Why Benefit: risk Assessment Should Drive Individualized Treatment Decisions
Session details

31 May I 18:30 – 19:45 CEST
UCB - Raising the Bar: Optimizing Outcomes in Spondylarthritis
Session details

31 May I 18:30 – 19:45 CEST
Janssen: IL-23 in PsA: connecting the domains of skin, gut, and joint
Session details

31 May I 18:30 – 19:45 CEST
GlaxoSmithKline - Is there a “window of opportunity" in SLE?
Session details

31 May I 18:30 – 19:45 CEST
AstraZeneca - Writing a new chapter in long-term lupus care
Session details

31 May I 18:30 – 19:45 CEST
Sobi - The many faces of inflammation: which cytokine should I target, when, and why?
Session details

 

1 June I 08:15 – 09:30 CEST

AbbVie - Tailoring PsA Therapy to Fit the Patient – Are Emerging Therapies Part of Your Collection?

Session details

 

1 June I 08:15 – 09:30 CEST

Lilly : Finding the right treatment for the right patient: what similarities and key differences among RA, PsA and axSpA determine treatment decisions

Session details

 

1 June I 08:15 – 09:30 CEST

Novartis - Getting to the root of PsA and axSpA

Session details

 

1 June I 08:15 – 09:30 CEST

GlaxoSmithKline - Shielding against shingles: how do we optimize care for our patients?

Session details

 

1 June I 08:15 – 09:30 CEST

AstraZeneca - Anifrolumab in SLE – perspectives from the real world

Session details

 

1 June I 08:15 – 09:30 CEST

EUSA - Unexplained lymphadenopathies: how a multidisciplinary approach can lead to a better diagnosis

Session details

 

1 June I 17:30 – 18:45 CEST

AbbVie - SpA on the Runway - A Front Row Seat for a Closer Look at the Latest Trends

Session details

 

1 June I 17:30 – 18:45 CEST

Pfizer - Connections between the gut, joint and spine: evidence and experience with JAK inhibitors

Session details

 

1 June I 17:30 – 18:45 CEST

UCB - The time is NOW! Aiming for higher treatment targets in PsA and axSpA

Session details

 

1 June I 17:30 – 18:45 CEST

Janssen : Moving closer to optimal pain management and timing intervention in PsA

Session details

 

1 June I 17:30 – 18:45 CEST

Boehringer Ingelheim - Optimising the management of patients with autoimmune disease-related ILDs through interdisciplinary discussions

Session details

 

1 June I 17:30 – 18:45 CEST

Galapagos - JAK to reality: seeking clarity in RA

Session details

 

1 June I 17:30 – 18:45 CEST

Celltrion Healthcare - Infliximab IV to SC: Mainstay Therapy in Rheumatology

Session details

 

1 June I 17:30 – 18:45 CEST

Vifor - Targeting unmet needs in ANCA-associated vasculitis – can we do better?     

Session details

 

2 June I 08:15 – 09:30 CEST
Pfizer - Unpacking the data: who are the appropriate patients with RA for a JAK inhibitor?

Session details

2 June I 08:15 – 09:30 CEST

Lilly - The Great Debate: Force of Habit vs. Innovative Approach in the management of inflammatory rheumatic diseases

Session details

 

2 June I 08:15 – 09:30 CEST

Medac - Improving first-line therapy of RA patients with optimized methotrexate

Session details

 

2 June I 08:15 – 09:30 CEST

GlaxoSmithKline - How Can We Tackle the Early Drivers of Organ Damage and Excess Mortality in SLE?

Session details

 

2 June I 08:15 – 09:30 CEST

Roche - Inspired to move mountains: optimising care in systemic lupus

Session details

 

2 June I 08:15 – 09:30 CEST

Otsuka - Lupus Nephritis: can we talk about a change of perspective today?

Session details

 

2 June I 08:15 – 09:30 CEST

Kyverna - CAR T Cell Therapy in B Cell Driven Autoimmune Diseases

Session details

 

2 June I 17:30 – 18:45 CEST

Lilly: The ”Case” for JAK Inhibitors- How JAK inhibition can be optimised in the treatment of varying RA patient populations, using case studies.

Session details

 

2 June I 17:30 – 18:45 CEST

Fresenius Kabi - Creating a Masterpiece in RA Management: How will new biosimilars shift the focus to alternative treatment strategies for your patients?

Session details

Consult the expert Programme overview

31 May I 15:45 – 16:15 CEST
Boehringer Ingelheim – “Monitoring and management of lung fibrosis in patients with autoimmune diseases”
Session details

31 May I 15:45 – 16:15 CEST

GlaxoSmithKline - Raising ambitions with clinical remission in EGPA

Session details

 

31 May I 15:45 – 16:15 CEST

Vifor - What the Rheumatologist needs to know about the kidney in ANCA-associated vasculitis

Session details

 

1 June I 09:45 – 10:15 CEST

Janssen: Partners in managing PsA: collaboration with Gastroenterology

Session details

 

1 June I 09:45 – 10:15 CEST

GlaxoSmithKline - Is there a window of opportunity in SLE?

Session details

1 June I 15:00 – 15:30 CEST

UCB - Facing the Challenges of the Impact of Gender in SpA

Session details

 

1 June I 15:00 – 15:30 CEST

Novartis - Advancing AOSD care: expert opinion on the latest guidelines

Session details

 

1 June I 15:00 – 15:30 CEST

GlaxoSmithKline - Can Disease Modification Help Us Tackle Organ Damage and Excess Mortality in SLE?

Session details

 

2 June I 09:45 – 10:15 CEST
Janssen - ​What would you do? An interactive discussion on PsA scenarios
Session details

2 June I 09:45 – 10:15 CEST
Galapagos - Burning questions: the practical use of JAK inhibitors in RA
Session details

2 June I 09:45 – 10:15 CEST

Vifor - Shared decision making in ANCA-associated vasculitis

Session details

2 June I 15:00 – 15:30 CEST

AstraZeneca - Treat to Target: how biologics can help?

Session details

 

* CEST (Central European Summer time)